ArticleOphthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)2026
Long-Term Outcomes and Predictors of Stepwise Atropine Concentration Adjustment in Paediatric Myopia Management.
Article in Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate long-term real-world treatment responses and baseline factors in children who received low-dose atropine for myopia control and required stepwise concentration adjustments.
methodsThis retrospective study included 651 of 1032 children (651 right eyes) aged 5-12 years at initiation, treated with daily atropine for at least 5 years (mean follow-up, 6.1 years). All began with 0.025% atropine, with escalation to 0.05%, 0.05% plus 0.025% in the late afternoon and finally to 0.125% at bedtime plus 0.025% in the late afternoon if the spherical equivalent (SE) showed a myopic shift ≥0.50 D over 6 months. Baseline characteristics were summarised across stepwise treatment pathways. A baseline-only Cox model was used to evaluate predictors of time to first escalation from 0.025 to 0.05%. Multivariable linear regression identified factors associated with annual SE change.
resultsMean age at baseline was 7.9 years, with annual SE and axial length (AL) changes of -0.41 D and 0.23 mm, respectively. Escalation from 0.025 to 0.05% occurred in 91.1%; of these, 70.8% required an additional 0.025% afternoon dose and 57.6% escalated to 0.125% plus 0.025% in the afternoon. Across stepwise comparisons, children requiring higher-intensity regimens tended to be younger and were less likely to show AL reduction at 3 months. In the baseline-only Cox model, younger age at initiation was independently associated with earlier escalation to 0.05% (p < 0.001). In multivariable regression, faster progression was most strongly associated with greater annual AL elongation (p < 0.001) and was also associated with younger age at initiation and SE ≤ -3.00 D at age 7-8 years (all p ≤ 0.02).
conclusionsMost children required escalation beyond 0.025%, and many progressed despite using 0.05% atropine. The mean annual SE change of -0.41 D suggests acceptable long-term myopia control under stepwise atropine adjustment, highlighting the need for early risk stratification and tailored strategies.
Indexed as
Identifiers
42274950What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.